Financial Architects, Inc Supernus Pharmaceuticals, Inc. Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 03, 2019	SELL	$32.77 - $41.99 $6,554 - $8,398	-200 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$30.84 - $49.51 $6,168 - $9,902	200 New	200 $7,000
Q2 2018 Aug 03, 2018	SELL	$44.1 - $59.85 $27,386 - $37,166	-621 Closed	0 $0
Q1 2018 Apr 23, 2018	SELL	$37.15 - $46.9 $4,197 - $5,299	-113 Reduced 15.4%	621 $28,000
Q4 2017 Feb 12, 2018	BUY	$36.4 - $42.6 $4,368 - $5,112	120 Added 19.54%	734 $30,000
Q3 2017 Nov 01, 2017	BUY	$36.75 - $49.65 $22,564 - $30,485	614	614 $25,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.